학술논문
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Document Type
Article
Author
Moreau, Philippe ; Hulin, Cyrille; Perrot, Aurore; Arnulf, Bertrand; Belhadj, Karim; Benboubker, Lotfi; Béné, Marie C; Zweegman, Sonja; Caillon, Hélène; Caillot, Denis; Corre, Jill; Delforge, Michel; Dejoie, Thomas; Doyen, Chantal; Facon, Thierry; Sonntag, Cécile; Fontan, Jean; Mohty, Mohamad; Jie, Kon-Siong; Karlin, Lionel; Kuhnowski, Frédérique; Lambert, Jérôme; Leleu, Xavier; Macro, Margaret; Orsini-Piocelle, Frédérique; Roussel, Murielle; Stoppa, Anne-Marie; van de Donk, Niels W C J; Wuillème, Soraya; Broijl, Annemiek; Touzeau, Cyrille; Tiab, Mourad; Marolleau, Jean-Pierre; Meuleman, Nathalie; Vekemans, Marie-Christiane; Westerman, Matthijs; Klein, Saskia K; Levin, Mark-David; Offner, Fritz; Escoffre-Barbe, Martine; Eveillard, Jean-Richard; Garidi, Réda; Ahmadi, Tahamtan; Krevvata, Maria; Zhang, Ke; de Boer, Carla; Vara, Sanjay; Kampfenkel, Tobias; Vanquickelberghe, Veronique; Vermeulen, Jessica; Avet-Loiseau, Hervé; Sonneveld, Pieter
Source
In The Lancet Oncology October 2021 22(10):1378-1390
Subject
Language
ISSN
1470-2045